Faeth Therapeutics
Develops PIKTOR, an oral cancer regimen designed to block multiple PAM-pathway nodes.
$33.84
After-hours close+0.16 (+0.48%)
At close$33.68(−0.18%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders —
Shares outstanding 25.78M · Float 18.61M
This issuer lists more than one class and the share count spans them all, so a stake here reads as a share of the whole company, not of this class.
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| S2G Investments, LLC | 9.99% | 2.58M | 13G | Jun 23, 2026 ↗ |
| Suvretta Capital Management, LLC | 7.80% | 2.02M | 13G | Jun 23, 2026 ↗ |
| Khosla Ventures VI, LP | 6.40% | 1.64M | 13G | Aug 14, 2026 ↗ |
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.